Investigational Drug Information for Peficitinib
✉ Email this page to a colleague
What is the development status for investigational drug Peficitinib?
Peficitinib is an investigational drug.
There have been 14 clinical trials for Peficitinib.
The most recent clinical trial was a Phase 3 trial, which was initiated on August 8th 2014.
The most common disease conditions in clinical trials are Arthritis, Rheumatoid, Arthritis, and Psoriasis. The leading clinical trial sponsors are Astellas Pharma Inc, Astellas Pharma Global Development, Inc., and Astellas Pharma China, Inc.
There are forty-four US patents protecting this investigational drug and six hundred and thirty-four international patents.
Summary for Peficitinib
| US Patents | 44 |
| International Patents | 634 |
| US Patent Applications | 210 |
| WIPO Patent Applications | 217 |
| Japanese Patent Applications | 58 |
| Clinical Trial Progress | Phase 3 (2014-08-08) |
| Vendors | 29 |
Recent Clinical Trials for Peficitinib
| Title | Sponsor | Phase |
|---|---|---|
| A Study to Evaluate the Pharmacokinetics and Safety of ASP015K in Healthy Chinese Subjects | Astellas Pharma China, Inc. | Phase 1 |
| A Study to Assess Safety and Efficacy of ASP015K in Patients With Rheumatoid Arthritis (RA) Who Had an Inadequate Response or Intolerance to Methotrexate (MTX) | Astellas Pharma China, Inc. | Phase 3 |
| A Drug Interaction Study to Evaluate the Pharmacokinetics of ASP015K and Metformin | Astellas Pharma Inc | Phase 1 |
Clinical Trial Summary for Peficitinib
Top disease conditions for Peficitinib
Top clinical trial sponsors for Peficitinib
US Patents for Peficitinib
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Peficitinib | ⤷ Sign Up | Cot modulators and methods of use thereof | GILEAD SCIENCES, INC. (Foster City, CA) | ⤷ Sign Up |
| Peficitinib | ⤷ Sign Up | Kinase inhibitors | Respivert Limited (High Wycombe, Buckinghamshire, GB) Topivert Pharma Limited (London, GB) | ⤷ Sign Up |
| Peficitinib | ⤷ Sign Up | Substituted indazoles for treating tendon and/or ligament injuries | NOVARTIS AG (Basel, CH) | ⤷ Sign Up |
| Peficitinib | ⤷ Sign Up | Kinase inhibitors | Respivert Limited (N/A) Topivert Pharma Limited (London, GB) | ⤷ Sign Up |
| Peficitinib | ⤷ Sign Up | Controlled release dosage form | TRIASTEK, INC. (Nanjing, CN) | ⤷ Sign Up |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Peficitinib
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Peficitinib | Argentina | AR108926 | 2036-06-30 | ⤷ Sign Up |
| Peficitinib | Australia | AU2017289158 | 2036-06-30 | ⤷ Sign Up |
| Peficitinib | Canada | CA3029457 | 2036-06-30 | ⤷ Sign Up |
| Peficitinib | European Patent Office | EP3478674 | 2036-06-30 | ⤷ Sign Up |
| Peficitinib | Spain | ES2800339 | 2036-06-30 | ⤷ Sign Up |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
